Lupin gets USFDA approval for suspension to treat allergic conjunctivitis
时间:2024-06-26 18:36:46 阅读(143)
Lupin gets USFDA approval for suspension to treat allergic conjunctivitis
Global pharma major Lupin Limited on Wednesday announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Loteprednol Etabonate Ophthalmic Suspension, 0.2 percent.
The approval has been granted to market a generic equivalent to the reference listed drug (RLD) Alrex Ophthalmic Suspension, 0.2%, of Bausch & Lomb Inc. The product will be manufactured at Lupin’s Pithampur facility in India.
Loteprednol Etabonate Ophthalmic Suspension, 0.2% (RLD Alrex), had estimated annual sales of USD 29.1 million in the U.S. (IQVIA MAT October 2023).
分享到:
温馨提示:以上内容和图片整理于网络,仅供参考,希望对您有帮助!如有侵权行为请联系删除!
猜你喜欢
- Nifty bounce back may face hurdle at 16800; watch Reliance, Titan, Vedanta, other stocks for action
- Market valuation of top-10 most valued firms jumps Rs 1
- ESAF Small Finance Bank IPO subscribed 73
- Mapmaking- Providing location data to the entire world
- MV Sai Baba not Indian-flagged vessel- Indian officials
- Nifty hovers around short-term average, faces stiff resistance; Bajaj Finserv, ITC, Tata Steel among top stocks to watch
- Maharashtra CM Eknath Shinde dredges up Kalyan Dargah issue, pledges ‘liberation’
- Mamaearth parent company Honasa surges 20% as Jefferies sees 25% upside
- Nifty closes near 21,658